These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 34518552)

  • 1. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?
    Weis LN; Tolaney SM; Barrios CH; Barroso-Sousa R
    NPJ Breast Cancer; 2021 Sep; 7(1):120. PubMed ID: 34518552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
    Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
    Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
    Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
    Vranic S; Basu GD; Hall DW; Gatalica Z
    Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
    Seligson ND; Knepper TC; Ragg S; Walko CM
    Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evolving landscape of tissue-agnostic therapies in precision oncology.
    Subbiah V; Gouda MA; Ryll B; Burris HA; Kurzrock R
    CA Cancer J Clin; 2024 May; ():. PubMed ID: 38814103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
    Thein KZ; Lemery SJ; Kummar S
    Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
    Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
    Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. If it's a target, it's a pan-cancer target: Tissue is not the issue.
    Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
    Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-Agnostic Cancer Therapy Approvals.
    Gouda MA; Subbiah V
    Surg Oncol Clin N Am; 2024 Apr; 33(2):243-264. PubMed ID: 38401908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparison of Post-marketing Measures Imposed by Regulatory Agencies to Confirm the Tissue-Agnostic Approach.
    Mulder J; van Stuijvenberg OC; van Hennik PB; Voest EE; Pasmooij AMG; Stoyanova-Beninska V; de Boer A
    Front Med (Lausanne); 2022; 9():893400. PubMed ID: 35775007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histology-agnostic drug development - considering issues beyond the tissue.
    Pestana RC; Sen S; Hobbs BP; Hong DS
    Nat Rev Clin Oncol; 2020 Sep; 17(9):555-568. PubMed ID: 32528101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
    Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Precision medicine becomes reality-tumor type-agnostic therapy.
    Yan L; Zhang W
    Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers.
    Boilève A; Verlingue L; Hollebecque A; Boige V; Ducreux M; Malka D
    Expert Opin Investig Drugs; 2021 Apr; 30(4):401-409. PubMed ID: 33641556
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of tissue-agnostic approvals on management of primary brain tumors.
    Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
    Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis.
    Cui Z; Zhai Z; Xie D; Wang L; Cheng F; Lou S; Zou F; Pan R; Chang S; Yao H; She J; Zhang Y; Yang X
    Front Pharmacol; 2024; 15():1329409. PubMed ID: 38357305
    [No Abstract]   [Full Text] [Related]  

  • 18. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
    Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
    Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
    Adashek JJ; Subbiah V; Kurzrock R
    Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.